Refractory Pulmonary Sarcoidosis
- 1 March 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Pulmonary Medicine
- Vol. 23 (2) , 67-75
Abstract
Patients with sarcoidosis undergo spontaneous remission or may be effectively controlled with glucocorticoids alone in many cases. Progressive and refractory pulmonary sarcoidoisis constitute >10% of the patients seen at specialized centers. Pulmonary fibrosis and associated complications, such as infections and pulmonary hypertension, are leading causes of mortality. No universal definition of refractoriness exists; we therefore propose classifying patients as having refractory disease when the following criteria are fulfilled: (1) progressive disease despite at least 10 mg of prednisolone or equivalent for at least 3 months and the need for additional disease-modifying antisarcoid drugs due to a lack of efficacy, drug toxicity, or intolerability; and (2) treatment started for significant impairment of life due to progressive pulmonary symptoms. Both criteria should be fulfilled. Treatment options in addition to or instead of glucocorticoids for these patients include second-line (methotrexate, azathioprine, leflunomide) and third-line agents (infliximab, adalimumab). Other immunmodulating agents can be used, but the evidence is very limited. Newer agents with antifibrotic properties, such as pirfenidone or nintedanib, might also hold promise for the pulmonary fibrosis seen in sarcoidosis. Treating physicians have to actively look for potentially treatable complications, such as pulmonary hypertension, cardiac disease, or infections before patients are classified as treatment-refractory. Ultimately, lung transplantation has to be considered as a treatment option for patients not responding to medical therapy. In this review, we aim to propose a new definition of refractoriness, describe the associated clinical features, and suggest the therapeutic approach.Keywords
This publication has 62 references indexed in Scilit:
- Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration vs Conventional Transbronchial Needle Aspiration in the Diagnosis of SarcoidosisChest, 2014
- An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort studyThe Lancet Respiratory Medicine, 2014
- Nonsteroidal therapy of sarcoidosisCurrent Opinion in Pulmonary Medicine, 2013
- Established and experimental medical therapy of pulmonary sarcoidosisEuropean Respiratory Journal, 2013
- Endobronchial Ultrasound–guided Transbronchial Needle Aspiration Prevents Mediastinoscopies in the Diagnosis of Isolated Mediastinal Lymphadenopathy: A Prospective TrialAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung functionEuropean Respiratory Journal, 2012
- SarcoidosisJAMA, 2011
- Rheumatologic Manifestations of SarcoidosisSeminars in Respiratory and Critical Care Medicine, 2010
- Presenting characteristics as predictors of duration of treatment in sarcoidosisQJM: An International Journal of Medicine, 2006
- Prognosis of Intrathoracic Sarcoidosis in EnglandBMJ, 1961